Savara Inc.

Savara Inc.

SVRA·NASDAQ

$5.32

+1.4%
HealthcareBiotechnology

Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.

At a Glance

Live Snapshot
Market Cap$1.09B
EPS-0.5300
P/E Ratio-10.05
Earnings Date08/06/2026

svra

Total Investments

Last Annual Value

202.52M

3-Year CAGR

40%

5-Year CAGR

28%

10-Year CAGR

30%

Savara Inc.

Savara Inc. Competitors Analysis of Total Investments

SVRA · NASDAQ
CompanyTotal Investments
CAGR 3Y
CAGR 5Y
CAGR 10Y
SVRA logo
Savara Inc.
NASDAQ:SVRA
202.52M
14.3%9.8%N/A 
518.14M
10.3%3.9%24.5%
321.65M
1.6%12.6%10.7%
RZLT logo
Rezolute, Inc.
NASDAQ:RZLT
73.75M
-10.3%N/AN/A
318.12M
N/AN/AN/A
230.86M
-5.1%-7.6%N/A
178.62M
7.1%N/AN/A
204.26M
60.1%44.0%31.0%
PROK logo
ProKidney Corp.
NASDAQ:PROK
161.48M
-18.9%N/AN/A
Savara Inc.

Savara Inc. Fair Value Envelope

SVRA · NASDAQ

Our analysis suggests that SVRA has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $5.3249, this represents a potential HIDDEN relative to our calculated worth for Savara Inc..

Intrinsic Value
Current Price: $5.3249